U.S. Markets closed

Response Genetics (RGDX) in Focus: Stock Up 18.3%

Zacks Equity Research

Response Genetics, Inc (RGDX) was a big mover last session, as its shares rose over 18% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the downtrend for the company since March 19, as the stock is now down over 4%.

In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Response Genetics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Other better-ranked stocks in the medical sector include ANI Pharmaceuticals, Inc. (ANIP), Alkermes plc (ALKS) and Alexion Pharmaceuticals, Inc. (ALXN). All three sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

RESPONSE GENETICS INC (RGDX): Free Stock Analysis Report

ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report

(ALKS): Free Stock Analysis Report


Zacks Investment Research